JW Shinyak Corporation (KOSDAQ:067290)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,682.00
-73.00 (-4.16%)
At close: May 15, 2026
Market Cap98.06B +13.6%
Revenue (ttm)81.04B -12.9%
Net Income15.66B +208.1%
EPS245.00 +295.2%
Shares Out55.87M
PE Ratio7.16
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume429,878
Average Volume428,347
Open1,798.00
Previous Close1,755.00
Day's Range1,674.00 - 1,798.00
52-Week Range1,288.57 - 2,670.00
Beta0.79
RSI30.56
Earnings DateMay 21, 2026

About JW Shinyak

JW Shinyak Corporation engages in the research, development, production, and sale of medicines and medical supplies in South Korea. It offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesity, and other products, as well as eye drops, and antitussives and expectorants. The company also develops prostate cancer treatment, liver cancer treatment, rheum... [Read more]

Industry Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Founded 1981
Employees 183
Stock Exchange KOSDAQ
Ticker Symbol 067290
Full Company Profile

Financial Performance

In 2025, JW Shinyak's revenue was 81.04 billion, a decrease of -12.87% compared to the previous year's 93.01 billion. Earnings were 15.66 billion, an increase of 208.11%.

Financial Statements